Agenus (AGEN) Q1 2025 earnings summary

Executive summary

• Presented new and mature data for BOT/BAL (Buckball), showing robust and durable responses in hard-to-treat tumors, including MSS colorectal cancer, TNBC, sarcomas, and liver cancers, with 100% pCR in dMMR CRC at higher doses.

• Announced the strategic hire of Dr. Richard Goldberg as Chief Development Officer to guide regulatory and clinical strategy.

• Four near-term transaction proposals received, including facility sale, equity investment at a premium, and two Buckball licensing deals, all aimed at strengthening the balance sheet.

• Operational efficiencies and cost optimization are on track to reduce annualized cash burn below $50 million in the second half of 2025.

• Regulatory environment is shifting favorably, with new FDA leadership emphasizing accelerated approval for transformative therapies.

Financial highlights

• Ended Q1 2025 with $18.5 million in cash, down from $40.4 million at year-end 2024.

• Q1 2025 revenue was $24.1 million, primarily from non-cash royalty revenue, compared to $28.0 million in Q1 2024.

• Net loss for Q1 2025 was $26.4 million ($1.03 per share), improved from $63.5 million ($3.04 per share) in Q1 2024.

• Cash used in operations for Q1 2025 was $25.6 million, reduced from $38.2 million in Q1 2024.

• Research and development expenses decreased 51% year-over-year to $21.5 million.

Outlook and guidance

• Anticipates announcing at least one major transaction (facility sale, equity, or licensing) in the coming weeks to bolster liquidity.

• Focused on securing accelerated approval for BOT/BAL in colorectal cancer, with a Type B FDA meeting requested on May 5 and productive CHMP engagement in Europe.

• Preparing to present updated clinical and late-stage pan-tumor activity data at a major upcoming conference.

• Cash resources expected to cover critical liquidity needs through Q2 2026, but additional funding is required for ongoing operations and product launches.